Section
Time-restricted eating performed similarly to individualized dietetic guidance for short-term HbA1c change in adults at risk of type 2 diabetes, but non-inferiority was not confirmed at 12 months. Benefits were small, and adverse events wer
A Danish registry study found no overall increase in selected cancers after gestational diabetes, but did observe a small absolute and relative increase in kidney cancer risk.
A large real-world study found that public implementation of intermittently scanned continuous glucose monitoring in insulin-treated type 2 diabetes was linked to better HbA1c, fewer acute diabetes hospitalizations, shorter stays, and lower
Post hoc SURPASS-CVOT analysis found tirzepatide lowered a broad 6-component cardiorenal composite versus dulaglutide in high-risk patients with type 2 diabetes, with more gastrointestinal adverse events but similar overall safety.
In treated Cushing syndrome, normal late-night salivary cortisol was linked to better mood, quality of life, and metabolic outcomes, suggesting circadian cortisol restoration may be a meaningful recovery target.
Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
Plasma profiling identified a three-miRNA panel associated with beta cell rate sensitivity across glucose tolerance stages, suggesting a minimally invasive approach to detect early insulin secretory decline.
A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascula
In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.
Long-term follow-up after two lifestyle trials found that reductions in visceral fat, more than overall weight loss, were linked to sustained cardiometabolic benefits and a lower risk of type 2 diabetes.
REIMAGINE 2 found that once-weekly cagrilintide-semaglutide lowered HbA1c more than semaglutide alone in adults with type 2 diabetes and overweight or obesity, with a safety profile consistent with known gastrointestinal effects.
In a SURMOUNT-1 post hoc analysis, tirzepatide improved multiple cardiovascular risk biomarkers over 72 weeks in obesity, with the largest and most consistent effects seen for inflammation, insulin resistance, adiposity-related markers, end
A validation study developed SABRE, a model that estimates how much SGLT2 inhibitors can reduce heart failure risk in people with type 2 diabetes, helping clinicians target preventive treatment more precisely.
The SABRE model estimates which people with type 2 diabetes may benefit most from SGLT2 inhibitors to prevent heart failure before it develops.
Acromegaly is often diagnosed late because symptoms are subtle. Serum IGF-I is the best screening test, OGTT confirms GH excess, and MRI localizes pituitary tumors. New AI and imaging tools may improve earlier detection.
A 2026 study identifies a biologically distinct obesity subphenotype marked by fast gastric emptying, low GLP-1 synthesis, and substantially greater 6-month weight loss with tirzepatide.
A 2026 review shows that many patients with acromegaly remain symptomatic and functionally impaired despite biochemical control, underscoring the need for routine patient-reported outcomes and lower-burden, multidisciplinary care.
In a large U.K. cohort, losing at least 15% of body weight within 2 years of type 2 diabetes diagnosis was linked to lower risks of heart, kidney, and eye complications, along with better glucose and blood pressure control.
A large retrospective study links higher HbA1c and elevated blood pressure to diabetic retinopathy in youth with type 1 diabetes, while worse glycemia also correlates with thinner inner retinal layers suggestive of early neurodegeneration.
